Ji Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ji Liu has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
Soshian Sarrafpour
Department of Ophthalmology and Visual Science, Yale School of Medicine, New Haven, CT, USA
5 shared publicationsChristopher C Teng
Department of Ophthalmology and Visual Sciences, University of Massachusetts Medical School, Worcester, MA, USA
4 shared publicationsChristopher C. Teng
Department of Ophthalmology and Visual Science, Yale School of Medicine, New Haven, CT, USA
3 shared publicationsAddiskidan Hundito
Yale School of Medicine, New Haven, CT, USA
2 shared publications- Angela C. Gauthier
Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore, MD, USA
2 shared publications Claudia A. Arrigg
Massachusetts Eye and Ear, Harvard Medical School
2 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-11
Outcomes of Selective Laser Trabeculoplasty for Sustained Elevation of Intraocular Pressure Following Intravitreal Anti-VEGF Injections
Purpose: To evaluate the efficacy and predictors of success of selective laser trabeculoplasty (SLT) for sustained elevation of intraocular pressure (SE-IOP) associated with anti-vascular endothelial growth factor (VEGF) therapy. Design: Retrospective observational case series. Methods: A retrospective chart review was performed for patients who received SLT following one or more anti-VEGF injections at an academic center between January 2013 and June 2022. Exclusionary criteria included history of non-open-angle glaucoma, incisional glaucoma surgery, or SLT more than 24 months after anti-VEGF injections. Main Outcome Measures: Outcomes included mean IOP and medication use up to 24 months following SLT. Failure was defined as less than 20% IOP reduction, increase in medication use, or need for additional laser or surgical interventions. Results: Thirty-three eyes of 31 patients were identified. Baseline IOP was 25.1 ± 6.1 mmHg on 2.7 ± 1.3 medications. SLT significantly reduced mean IOP but not medication use at all recorded time frames. At 24 months, mean IOP was 17.5 ± 8.2 mmHg (P = 0.009) on 3.1 ± 0.9 medications (P = 0.313). Success rates were 48.5% at 6 months, 32.3% at 12 months, and 23.6% at 24 months. The frequency of anti-VEGF injections (HR: 1.318; 95% CI: 1.072 to 1.623; P = 0.008) was the only significant predictor of SLT success in the multivariate analysis. Conclusion: SLT may be an effective adjunctive therapy for SE-IOP associated with anti-VEGF injections. The frequency of anti-VEGF injections prior to SLT may be a key predictor of treatment success.
- 1 July 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-11
Open AccessOutcomes of Selective Laser Trabeculoplasty for Sustained Elevation of Intraocular Pressure Following Intravitreal Anti-VEGF Injections
Purpose: To evaluate the efficacy and predictors of success of selective laser trabeculoplasty (SLT) for sustained elevation of intraocular pressure (SE-IOP) associated with anti-vascular endothelial growth factor (VEGF) therapy. Design: Retrospective observational case series. Methods: A retrospective chart review was performed for patients who received SLT following one or more anti-VEGF injections at an academic center between January 2013 and June 2022. Exclusionary criteria included history of non-open-angle glaucoma, incisional glaucoma surgery, or SLT more than 24 months after anti-VEGF injections. Main Outcome Measures: Outcomes included mean IOP and medication use up to 24 months following SLT. Failure was defined as less than 20% IOP reduction, increase in medication use, or need for additional laser or surgical interventions. Results: Thirty-three eyes of 31 patients were identified. Baseline IOP was 25.1 ± 6.1 mmHg on 2.7 ± 1.3 medications. SLT significantly reduced mean IOP but not medication use at all recorded time frames. At 24 months, mean IOP was 17.5 ± 8.2 mmHg (P = 0.009) on 3.1 ± 0.9 medications (P = 0.313). Success rates were 48.5% at 6 months, 32.3% at 12 months, and 23.6% at 24 months. The frequency of anti-VEGF injections (HR: 1.318; 95% CI: 1.072 to 1.623; P = 0.008) was the only significant predictor of SLT success in the multivariate analysis. Conclusion: SLT may be an effective adjunctive therapy for SE-IOP associated with anti-VEGF injections. The frequency of anti-VEGF injections prior to SLT may be a key predictor of treatment success.
- Open Access
- 1 June 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-11
Short-Term Preliminary Results of Outcomes with and without Tenonectomy During Open Conjunctival XEN45 Gel Stent Implantation
Purpose: To compare outcomes of eyes with and without tenonectomy during ab externo open conjunctival (AEO) implantation of a gelatin stent (XEN45 Gel Stent [XGS]) with mitomycin C. Methods: We conducted a retrospective comparative cohort study of adults aged ≥ 40 with open-angle glaucoma and preoperative intraocular pressure (IOP) > 17mmHg who underwent XGS AEO with or without tenonectomy at a single academic center (April 2021-September 2023). We matched eyes undergoing tenonectomy 1:3 to controls using nearest-neighbor algorithm. The primary outcome was success at 1 year (6 ≤ IOP ≤ 21mmHg, with ≥ 20% reduction from baseline, with or without IOP-lowering medication). Secondary outcomes included IOP, medication burden, visual acuity, and postoperative complications and interventions. Results: We included 40 eyes (38 patients): 10 with tenonectomy and 30 without. At 1 year, 70%, 60%, and 40% of tenonectomy eyes and 55%, 52%, and 36% of non-tenonectomy eyes achieved success at IOP thresholds of 21, 18, and 15 mmHg, respectively (all p> 0.05). There were no significant differences between groups in IOP, medication burden, or visual acuity. At 1 year, mean IOP was 14.83 ± 2.08 on 1.13 ± 0.38 IOP-lowering medications in the tenonectomy group and 16.88 ± 1.53 on 1.36 ± 0.31 medications in the non-tenonectomy group. Tenonectomy eyes tended toward more early complications (30% vs 23%, p=0.69), but fewer postoperative interventions (30% vs 57%, p=0.28) and reoperations (20% vs 30%, p=0.70). Conclusion: Both techniques provided effective IOP control and reduced medication burden. In this short-term preliminary study, tenonectomy may be more effective than the traditional technique. Given the small sample size and retrospective design, findings should be interpreted cautiously. More data are needed to guide optimal surgical technique.
- 1 June 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-11
Open AccessShort-Term Preliminary Results of Outcomes with and without Tenonectomy During Open Conjunctival XEN45 Gel Stent Implantation
Purpose: To compare outcomes of eyes with and without tenonectomy during ab externo open conjunctival (AEO) implantation of a gelatin stent (XEN45 Gel Stent [XGS]) with mitomycin C. Methods: We conducted a retrospective comparative cohort study of adults aged ≥ 40 with open-angle glaucoma and preoperative intraocular pressure (IOP) > 17mmHg who underwent XGS AEO with or without tenonectomy at a single academic center (April 2021-September 2023). We matched eyes undergoing tenonectomy 1:3 to controls using nearest-neighbor algorithm. The primary outcome was success at 1 year (6 ≤ IOP ≤ 21mmHg, with ≥ 20% reduction from baseline, with or without IOP-lowering medication). Secondary outcomes included IOP, medication burden, visual acuity, and postoperative complications and interventions. Results: We included 40 eyes (38 patients): 10 with tenonectomy and 30 without. At 1 year, 70%, 60%, and 40% of tenonectomy eyes and 55%, 52%, and 36% of non-tenonectomy eyes achieved success at IOP thresholds of 21, 18, and 15 mmHg, respectively (all p> 0.05). There were no significant differences between groups in IOP, medication burden, or visual acuity. At 1 year, mean IOP was 14.83 ± 2.08 on 1.13 ± 0.38 IOP-lowering medications in the tenonectomy group and 16.88 ± 1.53 on 1.36 ± 0.31 medications in the non-tenonectomy group. Tenonectomy eyes tended toward more early complications (30% vs 23%, p=0.69), but fewer postoperative interventions (30% vs 57%, p=0.28) and reoperations (20% vs 30%, p=0.70). Conclusion: Both techniques provided effective IOP control and reduced medication burden. In this short-term preliminary study, tenonectomy may be more effective than the traditional technique. Given the small sample size and retrospective design, findings should be interpreted cautiously. More data are needed to guide optimal surgical technique.
- Open Access
- 1 March 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-8
Quality Analysis of YouTube and Facebook Videos for Glaucoma Treatment Options
Purpose: Patients increasingly seek information about medical treatment options from the internet. This study evaluated the quality and accuracy of YouTube and Facebook videos on glaucoma treatment options. Methods: A comprehensive search of “glaucoma” and “eye pressure” combined with “treatment” or “cure” was performed. YouTube videos with at least 25,000 views and 25 views per day and Facebook videos with at least 1000 total views were included. Videos were excluded if they were not in English or about humans. The quality of videos was evaluated by two independent reviewers using a modified Currency, Relevance, Authority, Accuracy, and Criteria (CRAAP) metric. Videos were categorized as educational, testimonial, or advertisement. Results: A total of 74 YouTube videos and 19 Facebook videos were included. Of the YouTube videos, 89.7% were educational, 5.5% testimonials, and 4.8% adverts. Of the Facebook videos, 65.8% were educational, 21.1% testimonials, and 13.2% adverts. The inter-rater reliability was acceptable after kappa values were calculated. Fifteen percent of YouTube videos and eighteen percent of Facebook videos were graded as containing misinformation or misleading information. Audio and video quality scores were similar between categories. Higher accuracy and comprehensiveness scores were seen for educational videos. Seventy-four percent of YouTube videos and 66% of Facebook videos addressed the question of what is glaucoma, 65% of YouTube videos and 47% of Facebook videos discussed the course of untreated disease, 64% of YouTube videos and 34% of Facebook videos discussed the goals of treatment, and only 17% of YouTube videos and 0% of Facebook videos discussed the risks of the proposed treatment options. Conclusion: Patients are increasingly using YouTube and Facebook for medical information. This study found that many videos lack useful information and some provide information that may be detrimental. Physicians should be aware of this risk and educate patients appropriately.
- 1 March 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-8
Open AccessQuality Analysis of YouTube and Facebook Videos for Glaucoma Treatment Options
Purpose: Patients increasingly seek information about medical treatment options from the internet. This study evaluated the quality and accuracy of YouTube and Facebook videos on glaucoma treatment options. Methods: A comprehensive search of “glaucoma” and “eye pressure” combined with “treatment” or “cure” was performed. YouTube videos with at least 25,000 views and 25 views per day and Facebook videos with at least 1000 total views were included. Videos were excluded if they were not in English or about humans. The quality of videos was evaluated by two independent reviewers using a modified Currency, Relevance, Authority, Accuracy, and Criteria (CRAAP) metric. Videos were categorized as educational, testimonial, or advertisement. Results: A total of 74 YouTube videos and 19 Facebook videos were included. Of the YouTube videos, 89.7% were educational, 5.5% testimonials, and 4.8% adverts. Of the Facebook videos, 65.8% were educational, 21.1% testimonials, and 13.2% adverts. The inter-rater reliability was acceptable after kappa values were calculated. Fifteen percent of YouTube videos and eighteen percent of Facebook videos were graded as containing misinformation or misleading information. Audio and video quality scores were similar between categories. Higher accuracy and comprehensiveness scores were seen for educational videos. Seventy-four percent of YouTube videos and 66% of Facebook videos addressed the question of what is glaucoma, 65% of YouTube videos and 47% of Facebook videos discussed the course of untreated disease, 64% of YouTube videos and 34% of Facebook videos discussed the goals of treatment, and only 17% of YouTube videos and 0% of Facebook videos discussed the risks of the proposed treatment options. Conclusion: Patients are increasingly using YouTube and Facebook for medical information. This study found that many videos lack useful information and some provide information that may be detrimental. Physicians should be aware of this risk and educate patients appropriately.
- Open Access
- 15 December 2025
- Published by Jaypee Brothers Medical Publishing in Journal of Current Glaucoma Practice
- Vol. 19 (4) , 158-167
Surgical Outcome Comparison of Open Conjunctival Ab Externo Xen 45 Gel Stent Implantation vs Trabeculectomy in Open-angle Glaucoma
To evaluate the safety, efficacy, and risk factors for failure compared between trabeculectomy and open conjunctival ab externo Xen 45 gel stent (XGS AEO) placement. For this retrospective single-center study, we included eyes of patients >18 years old with open-angle glaucoma and baseline intraocular pressure (IOP) >17 mm Hg who received trabeculectomy or XGS AEO placement. We excluded aphakic eyes and those missing preoperative data. The primary outcome was the rate of success (6 ≤ IOP ≤ 21 mm Hg, plus ≥20% IOP reduction from baseline, with or without ocular hypotensive medications) after 1 year, compared between groups. Alternative IOP upper limits were 18 and 15 mm Hg. Secondary outcomes were risk factors for failure, complications, and postoperative interventions. We studied 82 trabeculectomy eyes and 34 XGS AEO eyes. At 1 year, 62%, 61%, and 49% of trabeculectomy eyes and 72%, 69%, and 31% of XGS AEO eyes achieved success using IOP upper limits of 21, 18, and 15 mm Hg, respectively. There were no 1-year intergroup differences in IOP, IOP percent change, visual acuity, complications, or revision surgeries. Medication use was higher in the XGS AEO group. Prior trabeculoplasty was associated with a lower risk for failure in the XGS AEO group, but an increased risk in the trabeculectomy group. More eyes in the trabeculectomy group underwent manipulations postoperatively (p = 0.020). Open conjunctival ab externo Xen placement is similar in efficacy and safety to trabeculectomy. The similar outcomes and fewer postoperative manipulations of XGS AEO implantation compared to trabeculectomy make it a reasonable surgical option in open-angle glaucoma. Applebaum SS, Hundito A, Teng CC, et al. Surgical Outcome Comparison of Open Conjunctival Ab Externo Xen 45 Gel Stent Implantation vs Trabeculectomy in Open-angle Glaucoma. J Curr Glaucoma Pract 2025;19(4):158–167.
- 15 December 2025
- Published by Jaypee Brothers Medical Publishing in Journal of Current Glaucoma Practice
- Vol. 19 (4) , 158-167
Open AccessSurgical Outcome Comparison of Open Conjunctival Ab Externo Xen 45 Gel Stent Implantation vs Trabeculectomy in Open-angle Glaucoma
To evaluate the safety, efficacy, and risk factors for failure compared between trabeculectomy and open conjunctival ab externo Xen 45 gel stent (XGS AEO) placement. For this retrospective single-center study, we included eyes of patients >18 years old with open-angle glaucoma and baseline intraocular pressure (IOP) >17 mm Hg who received trabeculectomy or XGS AEO placement. We excluded aphakic eyes and those missing preoperative data. The primary outcome was the rate of success (6 ≤ IOP ≤ 21 mm Hg, plus ≥20% IOP reduction from baseline, with or without ocular hypotensive medications) after 1 year, compared between groups. Alternative IOP upper limits were 18 and 15 mm Hg. Secondary outcomes were risk factors for failure, complications, and postoperative interventions. We studied 82 trabeculectomy eyes and 34 XGS AEO eyes. At 1 year, 62%, 61%, and 49% of trabeculectomy eyes and 72%, 69%, and 31% of XGS AEO eyes achieved success using IOP upper limits of 21, 18, and 15 mm Hg, respectively. There were no 1-year intergroup differences in IOP, IOP percent change, visual acuity, complications, or revision surgeries. Medication use was higher in the XGS AEO group. Prior trabeculoplasty was associated with a lower risk for failure in the XGS AEO group, but an increased risk in the trabeculectomy group. More eyes in the trabeculectomy group underwent manipulations postoperatively (p = 0.020). Open conjunctival ab externo Xen placement is similar in efficacy and safety to trabeculectomy. The similar outcomes and fewer postoperative manipulations of XGS AEO implantation compared to trabeculectomy make it a reasonable surgical option in open-angle glaucoma. Applebaum SS, Hundito A, Teng CC, et al. Surgical Outcome Comparison of Open Conjunctival Ab Externo Xen 45 Gel Stent Implantation vs Trabeculectomy in Open-angle Glaucoma. J Curr Glaucoma Pract 2025;19(4):158–167.
- Open Access
- 19 December 2024
- Published by Yale Journal of Biology and Medicine in The Yale Journal of Biology and Medicine
- Vol. 97 (4) , 491-503
Ocular Gene Therapy: An Overview of Viral Vectors, Immune Responses, and Future Directions
Ocular gene therapy has rapidly advanced from proof-of-concept studies to clinical trials by exploiting the unique advantages of the eye, including its easy accessibility, relative immune privilege, and the ability to use the contralateral eye as a ...
- 19 December 2024
- Published by Yale Journal of Biology and Medicine in The Yale Journal of Biology and Medicine
- Vol. 97 (4) , 491-503
Open AccessOcular Gene Therapy: An Overview of Viral Vectors, Immune Responses, and Future Directions
Ocular gene therapy has rapidly advanced from proof-of-concept studies to clinical trials by exploiting the unique advantages of the eye, including its easy accessibility, relative immune privilege, and the ability to use the contralateral eye as a ...
- Open Access
- 29 March 2024
- Published by Yale Journal of Biology and Medicine in The Yale Journal of Biology and Medicine
- Vol. 97 (1) , 41-48
External Disruption of Ocular Development in Utero
The intricate steps of human ocular embryology are impacted by cellular and genetic signaling pathways and a myriad of external elements that can affect pregnancy, such as environmental, metabolic, hormonal factors, medications, and intrauterine infections. ...
- 29 March 2024
- Published by Yale Journal of Biology and Medicine in The Yale Journal of Biology and Medicine
- Vol. 97 (1) , 41-48
Open AccessExternal Disruption of Ocular Development in Utero
The intricate steps of human ocular embryology are impacted by cellular and genetic signaling pathways and a myriad of external elements that can affect pregnancy, such as environmental, metabolic, hormonal factors, medications, and intrauterine infections. ...
- 3 March 2023
- Published by Springer Nature
- p. 291-311
Acute Pain Management Protocol for Ophthalmic Procedures
- 3 March 2023
- Published by Springer Nature
- p. 291-311
Acute Pain Management Protocol for Ophthalmic Procedures
- 23 April 2022
- Published by Springer Nature
- p. 2541-2560
Corticosteroid-Induced Glaucoma
- 2 November 2021
- Published by Wolters Kluwer Health in Journal of Glaucoma
- Vol. 31 (1) , 60-63
Anterior Subcapsular Cataract Formation With Long-term Topical Netarsudil Treatment for Glaucoma
Purpose: The purpose of this study was to describe anterior subcapsular cataract development in patients on long-term topical netarsudil use. Patients and Methods: This clinical observational study summarizes a similar cataract pattern demonstrated in a series of patients from a single physician practice and a university-based outpatient clinic during their routine clinical follow-up visits from October 2020 to August 2021. All patients have been using topical netarsudil once daily for at least 15 months. No anterior capsular changes have been observed in any patient at the time when netarsudil was initiated. Results: Five eyes from 4 patients between the ages of 41 and 61 and 1 eye from a patient aged 84 were found to develop anterior subcapsular opacities 15 to 37 months after beginning netarsudil. These cataracts were overall small, 1 to 3 mm, round, oval or ring-shaped, central or paracentral with mild density. No other risk factors for cataract development apart from age were found in these patients. Conclusion: Patients on long-term netarsudil should be monitored for potential development of anterior subcapsular cataracts.
- 2 November 2021
- Published by Wolters Kluwer Health in Journal of Glaucoma
- Vol. 31 (1) , 60-63
Anterior Subcapsular Cataract Formation With Long-term Topical Netarsudil Treatment for Glaucoma
Purpose: The purpose of this study was to describe anterior subcapsular cataract development in patients on long-term topical netarsudil use. Patients and Methods: This clinical observational study summarizes a similar cataract pattern demonstrated in a series of patients from a single physician practice and a university-based outpatient clinic during their routine clinical follow-up visits from October 2020 to August 2021. All patients have been using topical netarsudil once daily for at least 15 months. No anterior capsular changes have been observed in any patient at the time when netarsudil was initiated. Results: Five eyes from 4 patients between the ages of 41 and 61 and 1 eye from a patient aged 84 were found to develop anterior subcapsular opacities 15 to 37 months after beginning netarsudil. These cataracts were overall small, 1 to 3 mm, round, oval or ring-shaped, central or paracentral with mild density. No other risk factors for cataract development apart from age were found in these patients. Conclusion: Patients on long-term netarsudil should be monitored for potential development of anterior subcapsular cataracts.